ROIV - Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today? | Benzinga
Roivant Sciences Ltd (NASDAQ: ROIV) and Priovant's Phase 2 study of oral brepocitinib in moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus (SLE) Responder Index change of 4 (SRI-4) at Week 52.
Priovant plans to disclose the study data at a future date.
Also Read: Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal.
"We saw some of the highest SRI-4 responder rates ever observed ...